December 9, 2016 (Shareholders Foundation) - An investigation on behalf of investors of Agios Pharmaceuticals Inc (NASDAQ:AGIO) shares over potential securities laws violations by Agios Pharmaceuticals and certain of its directors and officers in connection certain financial statements was announced.

The investigation by a law firm focuses on possible claims on behalf of purchasers of the securities of Agios Pharmaceuticals Inc (NASDAQ:AGIO) concerning whether a series of statements by Agios Pharmaceuticals Inc regarding its business, its prospects and its operations were materially false and misleading at the time they were made.

Agios Pharmaceuticals Inc reported that its annual Total Revenue declined from $65.36 million in 2014 to $59.12 million in 2015 and that its Net Loss increased from $53.50 million in 2014 to $117.73 million in 2015.

At the 2016 American Society of Hematology meeting btween December 3 and 6, 2016, Agios Pharmaceuticals Inc presented new data for its AG-348 and AG-519 molecules, in development for treatment of pyruvate kinase deficiency.
Agios Pharmaceuticals Inc reportedly stated that a case of Grade 2 thrombocytopenia (a reduction of platelets in blood cells) was reported in a patient receiving AG-519, and that an ongoing severe adverse event of drug-related cholestatic hepatitis was observed in a bioavailability and food effect study after a dose of 300 mg.

Shares of Agios Pharmaceuticals Inc (NASDAQ:AGIO) declined from $67.25 per share in November 2016 to as low as $45.73 per share on December 7, 2016.